Hey, Alex, let me take the part of the question, this is Juan, on the same-store sales. Actually, all of the same-store sales that you see is basically Mexico because if you think about it, Chile, we haven’t really had the operation for a full year. So, the whole -- almost 11% that you see is basically the Mexico stores. And you’re correct that the expectation is that the same-store sales growth in Chile is going to be slower than that. I think what we’re going to see this quarter and the following three quarters, as we kind circle or lap around the integration of Socofar into the numbers, there are some differences in the P&L in terms of -- I mean stem already [ph] from the operation. As we mentioned in the remarks and in the press release, the gross margin tends to be higher Socofar, so the stores are bigger, the revenue per store is higher, prices are probably higher as well. But then also in terms of the expense structure, it’s higher, you need to have a pharmacist on site; you have more people at the store. Inventory levels are different, so there is also implication for D&A. At the end of the day, what we showed when we first did the transaction, EBITDA margin around 6%; that’s what we’re going to use kind of at the benchmark. Obviously this first quarter is seasonally a smaller quarter. So, there is a lot of kind of moving pieces that we’re going to have kind of transition into, as we go through the year. And because it is a large operation relative to the Mexico operation, it will impact the numbers. But just to the specific question about same-store sales growth, we’re not showing anything for Chile yet. But the expectation as you pointed out is that Mexico and perhaps Colombia, Colombia also has I think good chance for accelerated unit growth and same-store sales growth, but by and large, it’s all about Mexico in terms of the numbers you saw.